Search results for "thérapie"

showing 10 items of 41 documents

Titanate nanotubes as versatile nanovectors : radiosensitizers for the treatment of prostate cancer and nuclear imaging probes

2017

Currently, the systemic injections of drugs reach very weakly tumor sites and large doses are thus administered causing adverse side effects. The new implementations of nanoparticles in the medical field offer new strategies to vectorize an active substance in diseased cells. This work is focused on the prostate cancer, which is the second most frequently diagnosed cancer and the fifth leading cause of cancer death in men worldwide.Titanate nanotubes (TiONts) are synthetized by a hydrothermal process and have average dimensions of about 170 nm in length, 10 nm in outer diameter and also have an internal cavity of 4 nm in diameter. Their needle-shaped morphology allows them to be internalize…

Prostate cancerRadiotherapySpect[CHIM.THER] Chemical Sciences/Medicinal ChemistryFonctionnalisation[ CHIM.THER ] Chemical Sciences/Medicinal Chemistry[CHIM.THER]Chemical Sciences/Medicinal ChemistryCancer de la prostateTitanate nanotubesDocétaxel[PHYS.PHYS.PHYS-CHEM-PH] Physics [physics]/Physics [physics]/Chemical Physics [physics.chem-ph][ PHYS.PHYS.PHYS-CHEM-PH ] Physics [physics]/Physics [physics]/Chemical Physics [physics.chem-ph][CHIM.RADIO] Chemical Sciences/Radiochemistry[PHYS.PHYS.PHYS-CHEM-PH]Physics [physics]/Physics [physics]/Chemical Physics [physics.chem-ph]Nanotubes de titanateFunctionalization[CHIM.RADIO]Chemical Sciences/Radiochemistry[ CHIM.RADIO ] Chemical Sciences/RadiochemistryRadiothérapie
researchProduct

Role of myeloïd derived suppressive cells (MDSC) and Th17 lymphocytes in chemotherapy and immunotherapy efficacy

2017

Actual oncology is still facing resistance and rapid progression of cancer. Intrinsic resistance mechanisms developed by tumor cells determine chemotherapy and immunotherapy efficacy. It is now recognized that the host immune response status is in part implicated in the therapeutic outcome of patients. The aim of our research team is to characterize this response and to study the impact of therapies in order to identify the mechanisms associated with future exhaust of the tumor. In this context, we have shown that chemotherapy (5-FU, oxaliplatin, anti-VEGF: FOLFOX-bevacizumab) in some patients causes a drop in devices gMDSC (granulocytic myeloid derived suppressive cells) that is associated…

SIRT1[SDV.IMM] Life Sciences [q-bio]/ImmunologyImmunothérapieMDSCChemotherapyTh17ImmunotherapyChimiothérapieCancer
researchProduct

Ne sous-estimons pas le risque à long terme de second cancer pulmonaire après exérèse chirurgicale d'un cancer du poumon non à petites cellules

2019

Etat de la question Plusieurs etudes ont montre que les survivants d’un cancer du poumon sont a haut risque de developper un second cancer broncho-pulmonaire (SCBP). L’evaluation du risque de SPBC au cours du temps a d’importante repercussion sur la strategie de surveillance post-chirurgicale des cancers du poumon non a petites cellules (CPNPC). L’objectif principal de cette etude etait de mesurer le risque de SCP sur le long terme en tenant compte du risque competitif de deces. Materiel et methodes Le risque cumule de SCBP a ete estime a l’aide de l’incidence cumulee chez des patients operes en resection complete d’un CPNPC de stade I a III diagnostiques entre 2002 et 2015 et recenses par …

Second cancer broncho-pulmonaireEpidemiologyPublic Health Environmental and Occupational HealthRadiothérapie adjuvantesuivi[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieEnquête en populationCancer du poumon non à petites-cellulesComputingMilieux_MISCELLANEOUSRisque compétitifs3. Good health
researchProduct

Functional characterisation of the first HSP110 inhibitors.

2023

Heat shock proteins are molecular chaperones highly expressed in haematological malignancies. My laboratory has shown that the heat shock protein HSP110 is a new and important therapeutic target In colorectal cancer and in non-Hodgkin's lymphoma. As there were no existing inhibitors of HSP110, a screening strategy of a chemical library was carried out and allowed the identification of two molecules capable of specifically inhibiting the chaperone activity of HSP110. My thesis objective was to characterise and functionally validate these newly identified molecules in diffuse large cell B lymphomas. I have shown that one of these molecules limits the interaction of HSP110 with the SYK signall…

Signaling pathwaysVoies de signalisationHeat Shock Protein[SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyProtéine de choc thermiqueTargeted therapyActivated B Cell Diffuse Large B-Cell LymphomaLymphome B Diffus à Grandes Cellules de Type ActivéLymphome B Primitif du MédiastinCancer treatment[SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]Primary Mediastinal B cell LymphomaThérapie cibléeTraitements du cancer
researchProduct

Rapport annuel 2006-2007 de l'Observatoire national de la démographie des professions de santé.

2008

Ce troisième rapport de l'Observatoire national de la démographie des professions de santé comporte une synthèse générale assortie de préconisations et de quatre tomes thématiques : la médecine générale (tome 1), les internes en médecine (tome 2), la profession de chirurgien dentiste et les métiers de la périnatalité (tome 3), les métiers de la cancérologie (tome 4).

Spécialité médicale[SHS.SOCIO] Humanities and Social Sciences/SociologyEvolutionOffre soinsPédiatrieDémographie médicalePérinatalogieManipulateur électroradiologieNéonatologieInterneBloc opératoireDonnée statistiquePratique professionnelle[SHS]Humanities and Social SciencesSage femmeMédecine généraleProfession santéEquipement litFormation professionnelleInfirmier bloc opératoireOrganisation travailAnesthésieComputingMilieux_MISCELLANEOUSRadiothérapieChirurgien[SHS.SOCIO]Humanities and Social Sciences/SociologyChirurgien dentisteRégionHistoire professionnelleCancérologieGynécologie obstétrique[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie[SHS] Humanities and Social SciencesFranceMode exercice professionnelPuéricultriceQualitéEffectif
researchProduct

18F-FDG PET imaging of breast cancer : evaluation of the metabolic behaviour of the different breast cancer subtypes and prediction of the tumor resp…

2015

Positron Emission Tomography (PET) with 18Fluoro-deoxyglucose (18F-FDG) is the reference imaging examination for in-vivo quantification of the glucidic metabolism of tumour cells. It allows for the monitoring of tumour metabolic changes during chemotherapy. Breast cancer comprises several distinct genomic entities with different biological characteristics and clinical behaviours, leading to different tailored treatments. The aim of this doctoral thesis was to evaluate the relationship between the different biological entities of breast cancer and the tumour metabolic behaviour during neoadjuvant chemotherapy. We have also retrieved, among the various metabolic parameters on PET images, the …

Subtypes[SDV.IB] Life Sciences [q-bio]/BioengineeringFDGPositon EmissionTomographyRéponse tumoraleNeoadjuvant chemotherapyPhénotypesPETBreast cancerTEP[SDV.CAN] Life Sciences [q-bio]/CancerÉvaluationTomographie par Emission de PositonChimiothérapie néoadjucanteTumor responseCancer du sein[SPI.SIGNAL] Engineering Sciences [physics]/Signal and Image processing
researchProduct

Fluorescent organometallic complexes : when the photovoltaic leads to theranostics

2013

The goal of my PhD thesis was to synthesize new molecules, which give access to fluorescentorganometallic complexes with interesting properties for photovoltaic and theranostic. In thisproject, several main points have been studied.The first part of this manuscript concerns the synthesis of new metallocene and metalloporphyrinsbasedorganometallic complexes to the design of solar cells. After a short introduction, wepresented the synthesis of titanium complexes and metalloporphyrins in the first chapter. Inparticular, we described the synthesis of model compounds and the difficulties encountered duringthe transition to porphyrin derivatives. However, in view of results obtained and opportuni…

[CHIM.INOR] Chemical Sciences/Inorganic chemistryPorphyrinsThéranostiqueAnticancéreuxChimie organométalliqueCytotoxicity studiesOptical imagingChimie de coordinationCoordination chemistryPhotophysicsOrganometallic chemistryBODIPYsTheranosticPorphyrinesImagerie optiquePhotophysiqueEtudes de cytotoxicitéThérapieTherapyCancer
researchProduct

Hypofractionnated radiotherapy for elderly patients with prostate cancer

2018

Radiation therapy technique and schedules could be adapted to patient's age because of a natural history of prostate cancer perceived as different, taking into account the comorbidities of patients but also a particular tolerance of elderly subjects. Thus, in localized prostate cancer, evaluation of associated diseases is essential before considering a treatment that will be of interest only if the life expectancy is greater than 10 years. When a curative approach is decided, radiotherapy holds a place of choice. Due to the recent results of randomized studies evaluating moderate hypofractionnated radiotherapy, showing a carcinological equivalence compared to a standard fractionation, this …

[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingFractionation SchedulesNon-InferiorityProstate[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineRadiothérapie hypofractionnée Sujet âgé Cancer de la prostate OncogériatrieRadical ProstatectomyOlder MenGeriatric assessment[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicineIntensity-Modulated RadiotherapyQuality-Of-LifeElderly patientsExpectancy[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging[SDV.CAN] Life Sciences [q-bio]/CancerBeam Radiation-TherapyAndrogen-Deprivation TherapyHypofractionnated radiotherapyPhase-3 Chhip Trial
researchProduct

Effets secondaires thyroïdiens sous immunothérapie anti-PD1 : évaluation des facteurs de survenue

2018

Objectifs L’utilisation des immunotherapies anti-PD1 dans le traitement des cancers de la peau et du poumon, s’accompagne d’effets secondaires auto-immuns thyroidiens. L’objectif de cette etude etait de determiner leur frequence et d’identifier les facteurs favorisant leur survenue. Methodes Etude retrospective chez 196 patients traites pour un melanome malin ou un cancer bronchique non a petites cellules (CBNPC) par pembrolizumab ou par nivolumab, entre juillet 2014 et fevrier 2018. Quarante-quatre patients ont ete exclus de l’etude (34 pour antecedents de dysthyroidie et 18 par manque de donnees). Les dysthyroidies sous anti-PD1 ont ete differenciees des modifications de TSH par surcharge…

[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismEndocrinologyEndocrinology Diabetes and MetabolismImmunothérapie anti-PD1General Medicine
researchProduct

Thérapies ciblées et diabète

2017

[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismInhibiteur mTORthérapie cibléeComputingMilieux_MISCELLANEOUSdiabèteinhibiteur de tyrosine kinase
researchProduct